Akela Pharma Inc is categorized under Noncommercial Research Organizations in San Diego, CA and active since 2008.
Akela Pharma Inc was established in 2008, and today employs 1 to 4, earning $5.000.000 to $9.999.999 per year. This is a Noncommercial Research Organizations business, which does work in the B2B market, and is classified as a Noncommercial Research Organizations, under code number 541720 by the NAICS.
If you are seeking more information, feel free to contact Rudy Emmelot at the company’s single location by writing to 11011 Torreyana Road 100, San Diego, California CA 92121 or by phoning (512) 391-3525. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Akela Pharma Inc |
| Contact Person: | Rudy Emmelot |
| Address: | 11011 Torreyana Road 100, San Diego, California 92121 |
| Phone Number: | (512) 391-3525 |
| Annual Revenue (USD): | $5.000.000 to $9.999.999 |
| Founded: | 2008 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Noncommercial Research Organizations |
| SIC Code: | 8733 |
| NAICS Code: | 541720 |
| Share This Business: |
Akela Pharma Inc was started in 2008 to provide professional Noncommercial Research Organizations under the SIC code 8733 and NAICS code 541720. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $5.000.000 to $9.999.999 per annum.
Feel free to contact Rudy Emmelot for inquiries that concern Akela Pharma Inc by calling the company number (512) 391-3525, as your correspondence is most welcome. Additionally, the physical location of the single location of Akela Pharma Inc can be found at the coordinates 32.904879,-117.238048 as well as the street address 11011 Torreyana Road 100 in San Diego, California 92121.
For its online presence, you may visit Akela Pharma Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.